These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 8695819

  • 1. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy.
    Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S.
    Blood; 1996 Jul 15; 88(2):705-13. PubMed ID: 8695819
    [Abstract] [Full Text] [Related]

  • 2. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use.
    Porter JB, Rafique R, Srichairatanakool S, Davis BA, Shah FT, Hair T, Evans P.
    Ann N Y Acad Sci; 2005 Jul 15; 1054():155-68. PubMed ID: 16339661
    [Abstract] [Full Text] [Related]

  • 3. Intravenous chelation therapy during transplantation for thalassemia.
    Gaziev D, Giardini C, Angelucci E, Polchi P, Galimberti M, Baronciani D, Erer B, Maiello A, Lucarelli G.
    Haematologica; 1995 Jul 15; 80(4):300-4. PubMed ID: 7590497
    [Abstract] [Full Text] [Related]

  • 4. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.
    Evans P, Kayyali R, Hider RC, Eccleston J, Porter JB.
    Transl Res; 2010 Aug 15; 156(2):55-67. PubMed ID: 20627190
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Des Devel Ther; 2016 Aug 15; 10():465-81. PubMed ID: 26893541
    [Abstract] [Full Text] [Related]

  • 6. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ, Göbel U, Christaras A, Janssen G.
    Klin Padiatr; 2005 Aug 15; 217(3):120-5. PubMed ID: 15858702
    [Abstract] [Full Text] [Related]

  • 7. [Program of hypertransfusion and chelation with desferrioxamine in 10 patients with thalassemia major].
    Albo C, Cabrera J, Dios A, Castro M, Ares C, Constenla I, López D.
    Sangre (Barc); 1995 Dec 15; 40(6):441-5. PubMed ID: 8850225
    [Abstract] [Full Text] [Related]

  • 8. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.
    Abdelrazik N.
    Hematology; 2007 Dec 15; 12(6):577-85. PubMed ID: 17852442
    [Abstract] [Full Text] [Related]

  • 9. Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.
    Karakukcu C, Karakukcu M, Unal E, Patiroglu T, Ozdemir MA, Torun YA, Tang PH.
    Hemoglobin; 2012 Dec 15; 36(3):219-29. PubMed ID: 22483337
    [Abstract] [Full Text] [Related]

  • 10. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
    Kolnagou A, Kontoghiorghes GJ.
    Hemoglobin; 2006 Dec 15; 30(2):239-49. PubMed ID: 16798649
    [Abstract] [Full Text] [Related]

  • 11. The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation.
    Breuer W, Ronson A, Slotki IN, Abramov A, Hershko C, Cabantchik ZI.
    Blood; 2000 May 01; 95(9):2975-82. PubMed ID: 10779448
    [Abstract] [Full Text] [Related]

  • 12. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.
    al-Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV.
    Br J Haematol; 1992 Oct 01; 82(2):431-6. PubMed ID: 1419825
    [Abstract] [Full Text] [Related]

  • 13. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M, Assimakopoulos G, Polonofi K, Rigaki K, Aessopos A.
    Hemoglobin; 2008 Oct 01; 32(1-2):29-34. PubMed ID: 18274980
    [Abstract] [Full Text] [Related]

  • 14. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2008 Oct 01; 32(1-2):41-7. PubMed ID: 18274982
    [Abstract] [Full Text] [Related]

  • 15. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
    Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2006 Oct 01; 30(2):219-27. PubMed ID: 16798647
    [Abstract] [Full Text] [Related]

  • 16. Ferritin-associated iron induces neutrophil dysfunction in hemosiderosis.
    Cantinieaux B, Janssens A, Boelaert JR, Lejeune M, Vermylen C, Kerrels V, Cornu G, Winand J, Fondu P.
    J Lab Clin Med; 1999 Apr 01; 133(4):353-61. PubMed ID: 10218766
    [Abstract] [Full Text] [Related]

  • 17. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2009 Apr 01; 33(5):312-22. PubMed ID: 19814677
    [Abstract] [Full Text] [Related]

  • 18. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
    Voskaridou E, Komninaka V, Karavas A, Terpos E, Akianidis V, Christoulas D.
    Transfusion; 2014 Mar 01; 54(3):646-9. PubMed ID: 23834310
    [Abstract] [Full Text] [Related]

  • 19. Oxidative status and malondialdehyde in beta-thalassaemia patients.
    Cighetti G, Duca L, Bortone L, Sala S, Nava I, Fiorelli G, Cappellini MD.
    Eur J Clin Invest; 2002 Mar 01; 32 Suppl 1():55-60. PubMed ID: 11886433
    [Abstract] [Full Text] [Related]

  • 20. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
    Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, Sau F, Cianciulli P, Maggio A, Galanello R, Farci P.
    Blood Cells Mol Dis; 2010 Aug 15; 45(2):136-9. PubMed ID: 20678715
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.